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Summary
Objective: To review the basic scientific status of repair in articular cartilage tissue and to assess the efficiency of current clinical therapies
instigated for the treatment of structural lesions generated therein as a result of trauma or during the course of various diseases, notably
osteoarthritis (OA). Current scientific trends and possible directions for the future will also be discussed.
Design: A systematic and critical analysis is undertaken, beginning with a description of the spontaneous repair responses in different types
of lesion. Surgical interventions aimed at inducing repair without the use of active biologics will then be considered, followed by those
involving active biologics and those drawing on autogenic and allogeneic tissue transplantation principles. Cell transplantation approaches,
in particular novel tissue engineering concepts, will be critically presented. These will include growth-factor-based biological treatments and
gene transfection protocols. A number of technical problems associated with repair interventions, such as tissue integration, tissue retention
and the role of mechanical factors, will also be analysed.
Results: A critical analysis of the literature reveals the existence of many novel and very promising biologically-based approaches for the
induction of articular cartilage repair, the vast majority of which are still at an experimental phase of development. But prospective,
double-blinded clinical trials comparing currently practiced surgical treatments have, unfortunately, not been undertaken.
Conclusion: The existence of many new and encouraging biological approaches to cartilage repair justifies the future investment of time and
money in this research area, particularly given the extremely high socio-economic importance of such therapeutic strategies in the prevention
and treatment of these common joint diseases and traumas. Clinical epidemiological and prospective trials are, moreover, urgently needed
for an objective, scientific appraisal of current therapies and future novel approaches. © 2002 OsteoArthritis Research Society International.
Published by Elsevier Science Ltd. All rights reserved.
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The numerous experimental and clinical attempts that
have been made to induce the healing of histologic and
macroscopic lesions within mature articular cartilage aim at
re-establishing a structurally and functionally competent
repair tissue of an enduring nature. Such lesions are
generated during the course of many joint diseases,
notably osteoarthritis (OA), in conjunction with a large
number of genetic or metabolic conditions, such as
acromegaly, Paget’s Disease, the Stickler-Syndrome and
hemophilia (for review, see Buckwalter and Mankin)1, or
as a result of trauma. Traumatic lesions may occur
directly or indirectly in consequence of an intraarticular
fracture, a high-intensity impact or following ligament
injuries1,2.
Articular cartilage lesions generally do not heal, or heal
only partially under certain biological conditions. They are
frequently associated with disability and with symptoms
such as joint pain, locking phenomena and reduced or432disturbed function. Moreover, such lesions are generally
believed to progress to severe forms of OA1,3,4.
Given the multitude of possible origins, attempts to
heal articular cartilage lesions have obviously involved
symptomatic measures, which are useful only if patients
gain relief, if joint functionality can be significantly restored
and if the progression to severe joint destruction can be
prevented or at least materially slowed down4,5. Simple
arthroscopic interventions are currently of great interest in
the treatment of such lesions, their attraction being that
they can be repeated at low cost whenever necessary. By
these means, drastic measures of dealing with joint
destruction, such as total joint replacement, which is a risky
undertaking in elderly persons—the prime sufferers—could
be prevented.
This review article addresses the surgical and biological
attempts that have been made to induce a significant
and durable repair response6,7. It does not deal with the
medical treatment of painful joint states, nor with chondro-
protective strategies or measures that aim at improving
joint lubrication, since these undertakings do not aim at
healing structural lesions8–10.
This review article is organized in such a manner that we
initially consider lesion biologies within articular cartilage
tissue and specifically analyse the potential and limitations
of spontaneous repair responses. We then proceed first toReceived 19 June 2001; revision requested 21 August 2001;
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biologics and then to those involving them. Autogenic and
allogeneic tissue transplantation procedures are then dealt
with, followed by cell transplantation measures involving,
for example, autologous chondrocytes or embryonic cells.
One of the largest areas covered is the tissue engineering
approach to cartilage repair, in which not only cells and
matrices7,11,12 but also signaling substances or genetic
measures13 are employed for the re-establishment of a
structurally and functionally competent cartilage repair
tissue14–16. Finally, some of the specific biological and
technical problems commonly encountered with repair-
inducing protocols are addressed, for example, chondro-
cyte loss from the lesion borders, poor tissue integration
and mechanical factors7.
Each section of the review is dealt with in a systematic
manner: first the underlying biological concept is discussed
and then the available experimental and clinical data
analysed. At the close, the author offers the reader his
personal critical comments and a brief outlook of the future
in this field.protein and lipid, as well as, of course, red and white blood
cells, platelets containing many different releasable growth
factors, and various types of blood-borne cell32,33. Such a
blot clot can completely fill a defect void with a lateral
diameter of between 1 and 2 mm. Smaller or larger lesions
may not become fully occupied, and in these cases healing
is compromised23. The implication of these findings is that
an effective natural healing response occurs only within a
critical and narrow size range. The spontaneous repair of
smaller or larger lesions thus needs to be facilitated by the
insertion of a porous matrix that will imbibe blood or be
soaked by the hematoma in such a manner that the entire
void is permeated.
A spontaneously formed blood clot generally adheres
well to the surfaces of bony tissue, but only rarely so to
those of articular cartilage and to the defect floor and walls.
After a few days, mesenchymal cells begin to penetrate the
fibrin matrix, and within a matter of weeks this is completely
replaced by a vascularized, scar-like tissue27. Thereafter,
direct ossification processes, which may be quite exten-
sive, begin upon the bony surfaces. And within the repair
tissue itself, enchondral ossification activity is initiated. The
neo-ossification front generally proceeds upwards from the
sides and floor of the defect towards the joint cavity.
Interestingly though, the uppermost portion of the repair
tissue, which was originally occupied by the articular
cartilage layer, does not ossify but transforms into a fibrous
type of cartilage. This repair tissue manifests neither an
arcade-like organization of its fibers nor a well-defined
zonal stratification of its chondrocytes. Its biochemical
composition is indeed more akin to fibrous than to hyaline
cartilage34, and its mechanical competence is significantly
inferior to that of the latter35,36. It persists for some weeks
or even months but then inevitably begins to degenerate,
as does the fibrous type of repair cartilage laid down in
osteoarthritic individuals.
Spontaneously generated repair tissue integrates but
poorly with native cartilage, sites of focal discontinuity
being commonly encountered23. Not surprisingly therefore,
the collagenous fibrillar network of repair cartilage has
been found neither to project into native tissue nor to
intermingle with its fibrils.
Shapiro et al.27 and other investigators have noted
that the native articular cartilage immediately adjacent to
an artificially created defect site becomes necrotic after
surgery. Some chondrocyte-cluster formation occurs
therein, but it is neither remodeled nor resorbed. It appears
to remain essentially inert for some considerable time
before ultimately degenerating.
The heterogeneous composition and inferior bio-
mechanical properties of spontaneously formed repair
cartilage undoubtedly contribute to its functional incom-
petence and perishability. The compositional heterogeneity
is not surprising given the diverse origins of potential stem
cells and the uncontrollable influx of signaling substances
derived from the bone matrix, blood platelets and other
sources. These factors may also contribute to the highly
variable results achieved and to the unpredictable out-
come. Clearly, for a successful (reproducible and durable)
repair result, a more homogeneous repair cell population,
which is capable of producing hyaline-like cartilage, is
required.
As mentioned above, the spontaneous repair response
forms the basis for and the rationale behind a number of
surgical interventions that aim to induce the healing of
articular cartilage lesions. These therapeutic strategies will
now be discussed in detail.Lesion biology
During the course of OA, structural lesions typically
develop within the articular cartilage layer. The process is
initiated by the loss of proteoglycans from the extracellular
matrix and a disruption of the collagenous fibrillar network
therein, these events being followed by cell metaplasia and
loss. The initially small focal lesions gradually increase not
only in girth but also in length, such that ultimately the
entire thickness of the articular cartilage layer may be
destroyed (for review see17–21). Albeit that the metabolic
activity of the surviving resident population of chondrocytes
is augmented, this is altered in such a way that degrada-
tive processes predominate over anabolic ones22. It
has been known for decades that such lesions do not
heal spontaneously. The invidious process of destruction
advances downward until the osseous region is reached.
Once the bone and bone marrow spaces are involved in
the degradative process, local bleeding may occur, and
the ensuing local formation of a blood clot serves as
the basis for localized spontaneous repair activity during
OA.
The spontaneous repair of articular cartilage is thus
associated with defects that penetrate the bone and bone-
marrow spaces, being dependent upon the lesioning of
blood vessels, bleeding and hematoma formation. Various
types of stem cell are implicated, these originating from the
bone-marrow spaces, adipose tissue, vascular and peri-
vascular tissues and bone itself, as well as from the
synovium23–27. Large quantities of growth factors are also
released from the bone28–30, and these play an important
role in initiating the repair response. Full-thickness articular
cartilage defects created artificially for therapeutic pur-
poses during surgery are generated with a view to initiating
an analogous spontaneous repair response.
Since the physiological process of spontaneous repair
plays a key role in a number of surgically based strategies,
a thorough understanding of this response is of great
importance. Moreover, it illustrates the principles that must
be followed when endeavouring to modulate and boost
healing artificially.
The blood clot that forms the basis of the spontaneous
repair response27,31 consists principally of a fibrin matrix
within which are trapped various types of protein, glyco-
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LAVAGE AND ARTHROSCOPY
The irrigation or lavage of a joint with solutions of
sodium chloride, Ringer or Ringer and lactate, using
the closed-needle-hole procedure37, has been deemed
beneficial in osteoarthritic or trauma patients with painful
(mainly knee) joints. Simple exploratory arthroscopic pro-
cedures which involve thorough rinsing (unlike gas-based
arthroscopy) of the joint, have likewise been reported to
alleviate pain in several patient populations38,39.
Joint lavage was introduced as an empirical approach to
treating painful joint conditions involving structural
lesions39,40. There exists no scientific or biological basis to
account for the beneficial effects thereby derived. At best,
we can postulate that the extensive rinsing removes some
of the intraarticularly active pain-signaling or pain-
mediating molecules. It perhaps also extracts proteo-
glycans and aggrecans from the superficial cartilage matrix
compartment, thereby promoting, at least transiently, the
adhesion of repair cells41, which may prompt an antiinflam-
matory response. But no solid evidence of any biological or
repair activity being instigated by lavage is available42.
Some investigators have reported the beneficial effects
of lavage to persist for one year or more39, whereas others
have observed no substantial relief from pain in patients
who have undergone this treatment43. In yet other
studies—principally those in which lavage was conducted
in conjunction with arthroscopy—the benefits have been
attributed to a placebo effect of the surgical intervention
per se38. The placebo effect of surgery is, indeed, not to
be underestimated, and the considerable bias introduced
during clinical assessment and by different joint-scoring
systems have also to be taken into account44,45.
Taking the available data as a whole37, lavage does
appear to have a beneficial effect for limited periods of time,
irrespective of whether this is performed by the closed-
needle-hole technique or in association with arthroscopic
intervention43,46,47. In their controlled randomized clinical
trial, Chang et al.37 observed no difference between the two
groups for periods of up to one year, at which time 50% of
the treated population had some relief from pain. Moreover,
patients who had a history of trauma (such as tearing of the
cruciate ligament or meniscus, or traumatic structural
lesioning) derived greater benefits than did those suffering
from OA38–40.
SHAVING
Chondral shaving is generally carried out by arthroscopic
intervention and aims at the mechanical removal of dis-
eased chondral tissue using appropriate surgical instru-
ments. Nowadays, it is performed infrequently and
mainly recommended for chondromalacia patellae or
patello-femoral pain48.
The biological rationale behind this empirical type of
intervention is by no means clear. It may represent merely
an intuitive move by the surgeon to do the patient ‘some
good’ by removing the fibrillated articular cartilage seen
by arthroscopic inspection, and by thus ‘smoothing the
surface’ reduce possible friction. But from a biomechanical
point of view49–51, such an undertaking makes no sense at
all.
Experiments with mature rabbits52 have revealed no
evidence whatsoever of repair tissue at defect sites up to12 weeks after chondral shaving, irrespective of the bio-
mechanical loading protocol applied to the joint. Moreover,
the remaining cartilage underwent degeneration. This
phenomenon, which is probably attributable to apoptotic
cell loss53, has been observed also by Mitchell and
Shepard54. It likewise occurs along lesion borders27 and
has been shown quantitatively to involve a substantial cell
loss55.
In one clinical investigation conducted by Ogilvie-Harris
and Jackson48, shaving was found to be advantageous
only in a subgroup of patients suffering specifically from
post-traumatic joint pain; not in those with femoral pain
states. But since no prospective randomized clinical
trials have been undertaken, it is impossible to assess
the usefulness of this intervention. And on the basis of
laboratory data, it is certainly not justified.
DEBRIDEMENT
Debridement is a more drastic version of the shaving
procedure, combining this latter undertaking with lavage,
meniscectomy, the removal of free bodies from the joint
and the limited excision of osteophytes56.
As in the case of shaving, there exists neither a sound
scientific basis for performing debridement nor any evi-
dence from animal experiments of beneficial biological
effects derived therefrom. Indeed, if one considers articular
cartilage biology and joint biomechanics, one would expect
debridement to have deleterious consequences for joint
biology. As mentioned in the previous section, shaving
(chondrectomy) is associated with cell apoptosis and
necrosis52–54. In addition to this, meniscectomy will lead to
skeletal malalignment and a change in the transarthrodial
loading pattern. In the long term, this treatment has been
shown both experimentally57,58 and clinically59,60 to
exacerbate the osteoarthritic condition. Debridement is
thus undertaken clinically as a purely palliative measure to
relieve patients temporarily of pain in an osteoarthritic joint.
In default of a rational biological concept underlying this
procedure and in the complete absence of experimental
evidence to justify the intervention, it is not surprising
that clinical findings pertaining thereto are highly variable,
ranging from good (pain relief in 65% of patients)56,61,62
through moderate (pain relief in less than 50% of
patients)63,64 to very poor43,65,66. Even when the results
are reportedly good, the temporary nature of the benefits
derived are always stressed by the investigators.
All published reports are based on subjective retrospec-
tive studies and are thus of very limited value in yielding
meaningful information5,44,45. Regrettably, no prospective,
double-blinded clinical trials have been carried out. An
objective gounding for performing debridement is thus not
available.
LASER ABRASION/LASER CHONDROPLASTY
Laser chondroplasty may be used as an alternative to
the surgical removal of tissue by mechanical cutting. One of
the advantages of employing laser light (of certain wave-
lengths) as a cutting tool is that it coagulates tissue67, and,
unlike electrothermal cutting instruments, which generate
temperatures of up to 250°C, can be used in an aqueous
environment68,69.
Obviously, in the case of articular cartilage, which is
avascular, or meniscal tissue, which is only poorly vascu-
larized, blood coagulation is not a prime consideration.
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an aqueous environment, lasers are certainly preferable to
conventional electrothermal instruments in that they avoid
water-boiling effects within the rinsing media. Moreover,
flexible tubes can be used for the transmission of certain
types of laser light, such as neodymium: YAG68. Further-
more, laser radiation is also useful for tissue welding and
fusion70,71.
The biological rationale behind the use of lasers in
chondroplastic surgery is thus that they serve as gentle
cutting instruments72,73, not that they induce articular
cartilage repair, although questionable claims of a bio-
stimulatory effect of laser radiation have been reported74.
There exists no more justification for performing surgical
shaving and debridement with laser light than there does
for carrying out these procedures by means of mechanical
cutting, no repair of articular cartilage having been reported
as a consequence of either undertaking. Indeed, laser
chondroplasty has not been subjected to a thorough
investigation in experimental animals75. Many different
sources of laser light have been tested for chondroplastic
purposes in a laboratory setting, including carbon dioxide,
neodymium: YAG76, holmium: YAG77, erbium: YAG78 and
Excimer79. The effects produced depend greatly upon
wavelength, frequency and energy level, a discussion of
which lies beyond the scope of this section. It will suffice
here to mention the undesired consequences of such
treatment with most, but not all, types of laser; these relate
to thermal damage, air-bubble formation77,78 and tissue
necrosis78. The main complications associated with the
clinical use of lasers in chondroplasty are osteo-
necrosis80,81, reactive synovitis, chondrolysis and an
acceleration of articular cartilage degeneration82,83.
The reported biostimulatory effects of laser light alluded
to above are based on experiments with dedifferentiated
chondrocytes in two-dimensional culturing systems: such
cells were found to manifest an increased proliferative
activity74. These findings are, however, not convincing. In
the first place, the behavior of chondrocytes in vivo is
fundamentally different from that of dedifferentiated ones in
two-dimensional cultures. And then, the observed response
may have been attributable to a thermogenic effect rather
than a direct consequence of laser irradiation, which would
be more likely to slow down proliferative activity, as a result
of nuclear damage. Indeed, the use of lasers is consistently
associated with cell and tissue necrosis.
Tissue welding or fusion effects induced by laser light
have not been quantified in the case of cartilage, but the
adhesion elicited is unlikely to be sufficiently strong and
extensive to withstand the high mechanical demands of
joint tissues84.
Clinical findings pertaining to laser chondroplasty give a
falsely over-optimistic view69,85, good to excellent (65% to
85%) results having been reported. These data are based
on retrospective studies, which are generally useful only in
addressing safety issues and in appraising certain side-
effects. Conclusive information respecting the putative
advantages of laser-based over conventional approaches
cannot be furnished unless prospective, double-blinded
clinical trials are undertaken. One instance of a single- (not
double-) blinded prospective study83 has revealed mech-
anical meniscectomy to yield better clinical results than the
laser-induced approach. Hence, in this instance at least,
the high-cost use of lasers is not justified.
Although clinical experience with lavage, shaving,
debridement and laser chondroplasty dates back more
than 10 or 15 years, the surgical community has failed toundertake the prospective clinical trials that would provide
the necessary information to justify the performance of
any one of these methodologies or substantiate claimed
positive effects.
ABRASION CHONDROPLASTY
Abrasion chondroplasty, as well as Pridie drilling and the
microfracture technique (see following sections), involve
surgical access to the bone-marrow spaces, which,
together with other vicinal compartments (such as the
vascular and perivascular spaces, the bone tissue itself
and adipose tissue), are consequently stimulated. These
three interventions essentially lead to a spontaneous repair
response, which is based upon therapeutically-induced
bleeding from the subchondral bone spaces and subse-
quent blood-clot formation. The provocation of such a
spontaneous repair response is well known from animal
experiments to yield highly variable and non-reproducible
healing results, the tissue formed being fibrous in nature34
and not durable27. These techniques were introduced more
than 20 years ago, at which time no alternative or better
strategies were available, and in the intervening years a
considerable body of clinical experience has been gained
with them.
Laboratory experiments relating to abrasion chondro-
plasty of the knee joint have been conducted in both
rabbits52,86 and dogs31. Findings confirm that the spon-
taneous repair response originates from the bone-marrow
spaces and results in the formation of a fibrous type of
cartilage tissue. Although this contains most of the matrix
components found in hyaline cartilage, significant
quantities of fibrous constituents are also present34. In
rabbits subjected to Pridie drilling, repair tissue endured for
a longer period than did that in animals treated by abrasion
chondroplasty86. It has been proposed that if an appropri-
ate biomechanical treatment schedule, such as continuous
passive motion52, is instigated following abrasion chondro-
plasty, then the hyaline quality and endurance of the repair
cartilage may be somewhat improved87. On the basis of
these animal experiments, a long-term cure cannot
be expected from the performance either of abrasion
chondroplasty, Pridie drilling or the microfracture technique.
Various retrospective clinical investigations pertaining to
abrasion chondroplasty have been conducted6,38,88,89. The
success rates are variable90 and depend on many factors,
such as the patient’s age and activity level, the severity of
the arthritic condition and the follow-up period. Only one
relevant clinical trial has been undertaken91. In this,
patients suffering from OA and painful knee conditions were
subjected either to concomitant abrasion chondroplasty
and osteotomy or to osteotomy alone. Individuals treated
by the combined approach manifested a significantly higher
proportion of hyaline-like cartilage repair tissue and had a
lower incidence of tissue degeneration 12 months after
surgery than did those who received only an osteotomy.
However, no difference in the clinical outcome was
observed after 2 (and up to 9) years.
PRIDIE DRILLING
The idea of drilling therapeutic holes into the subchon-
dral bone-marrow spaces underlying regions of damaged
articular cartilage was conceived by Pridie in 195992–94.
And, as mentioned in the previous section (ABRASION
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to stimulate a spontaneous repair reaction. But, perforce,
the tissue formed is variable in composition, structure and
durability. The intervention is now performed chiefly in
patients with painful osteoarthritic conditions, such as
osteochondritis dissecans92, in an attempt to bring symp-
tomatic relief and to improve joint functionality95,96 by
promoting resurfacing with fibrocartilaginous repair tissue.
One study conducted in Germany97 has revealed Pridie
drilling to represent the surgical procedure most frequently
adopted in this country for the treatment of osteochondritis
dissecans, it being performed much more often than
abrasion arthroplasty (chondroplasty).
In laboratory experiments with rabbits98, Pridie drilling
has been demonstrated to result in the formation of fibro-
cartilaginous repair tissue. Moreover, post-operative joint
inflammation was found to be not an exclusively abrasion-
related phenomenon but rather, and generally, a surgically-
associated one. Removal of debris from the joint by
irrigation prior to wound closure is deemed advisable
to ameliorate both acute and chronic post-surgical
inflammation98.
Clinical reports suggest that patients suffering from
generalized arthroses derive the greatest benefits from
Pridie drilling99. Although it appears to be a fairly safe
procedure100, the superiority of Pridie drilling over other
surgical interventions remains to be established, the
appropriate prospective, clinical, epidemiological studies
having not, as yet, been undertaken. This procedure
appears, however, to confer only short-term benefits; in the
long-run (several years after surgery), these are lost101.
Indeed, in young patients suffering from severe chondral
damage in weight-bearing regions of the knee joint, the
long-term spontaneous improvement (i.e., that achieved in
the absence of surgery) is not inferior to that elicited by
surgical intervention102.
MICROFRACTURE TECHNIQUE
The microfracture technique represents no more than a
modificaton of Pridie drilling and thus relies on the same
biological principles. Animal experiments confirm that the
same type of repair tissue is formed103. The microfracture
technique was elaborated by Steadman et al.104, who
recommended that the very small micro-holes generated
be distributed across the entire articular cartilage lesion
site, at a distance of 3–4 mm apart and down to a depth of
4 mm, thus yielding about 3–4 holes per cm2. Since the
holes drilled are considerably smaller (approximately
0.5–1.0 mm in diameter) than those created by Pridie
drilling (approximately 2.0–2.5 mm in diamter), perforation
of the subchondral bone plate is such as to disturb its
biomechanics less drastically. The particular advantages of
the microfracture technique are that it can be performed
by a minimally invasive arthroscopic approach, which
requires no costly instrumentation and induces only
minimal iatrogenic tissue damage.
The microfracture technique has been applied chiefly in
young athletes and in young patients generally. In such
individuals, good results (improved joint functionality and
relief from pain in 75% of cases) have been reported105.
Clinical experience gained with osteoarthritic patients has
not been published. Indeed, it is questionable whether this
technique would be an appropriate one to apply in such
individuals, whose spontaneous tissue repair potential is
impoverished and in whom the availability of bone-marrow-derived mesenchymal stem cells is reduced106–108. The
technique has been applied with some success also in
veterinary medicine (in horses)109. Once again though, no
prospective clinical trials have been undertaken that would
confirm or refute the claimed advantage of this over other
surgical interventions.
SPONGIALIZATION
Spongialization110, like Pridie drilling, is based upon the
stimulation of a spontaneous tissue healing response. It is
applied chiefly in patellar surgery to treat very localized
defects. It involves complete removal of the subchondral
bone plate at the lesion site, thereby exposing the cancel-
lous bone or spongiosa. Bleeding ensues and repair tissue
is laid down within the milieu of the resulting blood clot.
Experimental data pertaining to this technique are not
available, from which circumstance one may conclude that
it has been tested directly in human patients.
Clinical reports101,110 document the usual good to excel-
lent results (improved joint functionality and relief from pain
in 70–80% of patients) which are invariably yielded when a
single group of surgeons favors a particular procedure.
Although serious drawbacks associated with this technique
have not been reported, it has not gained great popularity.
Overall, the few potential benefits to be derived from
applying this fairly aggressive and destructive approach are
of questionable value111.Extensive surgical interventions
OSTEOTOMY
High-tibial osteotomy is one of the palliative surgical
procedures most frequently adopted for the treatment of
painful OA. But it is also undertaken as a corrective
measure for large extraarticular deformities, such as those
affecting the valgus or varus, which can occur in associ-
ation with osteo- or rheumatoid arthritis. Severe joint
deformities represent complex disturbances in the align-
ment of ligaments and the underlying muscular apparatus,
which are now more frequently treated by combined oste-
otomy and total knee-joint arthroplasty112,113. Osteotomy is
thus undertaken with a view not to inducing articular
cartilage repair but to relieving pain and to improving
alignment as well as biomechanical load transfer in knee
joints. It is known empirically that surgical realignment
induces a change in contact pressure and contact areal
coverage within a knee joint. When such adjustments are
made in cases of painful OA, patients are usually relieved
of pain for a considerable time. Hence, in these instances,
osteotomy serves to alleviate painful symptoms.
When this treatment principle is considered from a
biological point of view, it would be expected to have a
deleterious effect on cartilage repair and to exacerbate the
degeneration of this tissue as a consequence of
osteotomy-induced local mechanical overloading. This is
perhaps the reason why osteotomy is often combined with
other interventions, such as shaving or abrasion chondro-
plasty91,95. Hence, osteotomy is not usually recommended
for painful osteoarthritic conditions with no associated
deformities. When conducted alone, it tends to be reserved
for severe cases of unicompartmental knee-joint OA or for
severe knee joint deformities114–116.
Laboratory experiments with rabbits117 and dogs118,119
confirm that osteotomy-induced changes in joint alignment
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onset of a slow but progressive osteoarthritic process,
which does not occur in sham-operated controls118. Typical
osteoarthritic changes are wrought within the articular
cartilage layer, such as proteoglycan loss, fibrillation, and
the formation first of clefts and then of structural defects.
Subchondral bone density is also increased117. Mal-
alignment of the femoral patella accompanied these patho-
logical changes and affected also the tibial femoral joint
line. When the destruction of articular cartilage tissue
reaches the bony compartment, focal bleeding occurs, this
being followed by a localized spontaneous healing
response. Such activity is a usual accompaniment of the
late osteoarthritic process and is not a direct consequence
of osteotomy. In some studies120, these issues may have
been confused by the investigators. Clearly, though, a
distinction between different types of repair activity cannot
be made in human patients, since tissue formation cannot
be monitored clearly and progressively with time. Not
surprisingly therefore, some authors121 have encountered
only a few islands of repair cartilage in patients who have
undergone osteotomy, whereas in those who have
received this treatment in combination with abrasion
chondroplasty or Pridie drilling, a better coverage with
fibrocartilaginous tissue was achieved.
Many different combinations of osteotomy with other
surgical interventions have been applied, respecting
which there exists a fairly sophisticated indication
scheme114,122–125. Clinical experience with these different
combinations has been generally good to very good,
success rates of between 70% and 85% having been
reported95,120,126,127. However, it has not been possible to
draw any conclusions as to which couplings for which
indications yield the best results120, since no differences
in the success rates between the various therapeutic com-
binations have been reported. And, once again, the pro-
spective, double-blinded, comparative clinical trials that
would furnish the necessary information have not been
undertaken.
DISTRACTION OF JOINTS
Joint distraction has been forwarded as a treatment
mode for OA with a view to reducing pain and prolonging
the time elapsing before it becomes necessary to perform
an arthrodesis128,129. This measure has also been postu-
lated to promote an articular cartilage repair response
within the treated joint, usually the ankle129.
There exists no rational biological basis for this therapy,
since it has been known for decades that joint immobiliz-
ation leads ultimately to the degeneration of articular
cartilage. Indeed, experiments with rabbits have shown that
continuous distraction of synovial joints induces changes
within the articular cartilage layer130 that are similar to
those observed in osteoarthritic tissue, including loss of
proteoglycans, chondrolysis and a diminution in its thick-
ness131. Similar effects have been observed after tibial
lengthening in the same animal model132 and after lumbar
spine133 as well as tibial134 distraction in dogs. In view
of these findings, the clinically beneficial effects on
immobilized joints documented by van Valburg et al.128 are
somewhat surprising. They are attributed by the authors to
intermittent changes in fluid pressure of low physiological
magnitude. However, this interpretation is inconsistent with
current basic intelligence indicating that intermittent
changes in fluid pressure have a stimulatory effect onTheraputic interventions with active biologics
AUTOLOGOUS TISSUE TRANSPLANTATION
Perichondrial/periosteal grafts
The chondrogenic potential and repair-promoting
properties of perichondrial tissue were first recognized by
Haebler et al.137 in 1925, but their findings were not
confirmed until a further 30 years had elapsed138. Even so,
it was not until the 1970s that perichondrial or periosteal
tissue was utilized as an autotransplantation material for
repair induction in articular cartilage defects139–141. Since
then, the principle has been exploited in a variety of
protocols instigated for the treatment of articular cartilage
lesions142–150.
The biological rationale behind this transplantation
principle lies in the observation that the cambial (i.e.,
germinative) layer of perichondrial (or periosteal) tissue
manifests continuous, life-long, chondrogenic (or osteo-
genic) activity137,138,151. A pool of adult-type stem cells
must therefore reside in this germinative layer and be
capable of reactivation for tissue neoformation. The
assumption made in adopting this principle is that when
such a tissue graft is laid, cambial layer uppermost152, on
the floor of a full-thickness articular cartilage defect, its
proliferative and tissue-differentiation activities will be
resumed and result in the formation of repair cartilage
within the lesion void.
Various in-vitro153–156 and in-vivo studies (mainly with
rabbits)157–162 have been conducted in defence of this
principle. The latter mostly reveal some neoformation of
cartilage-like tissue163,164, although authors who have
undertaken quantitative analyses have observed spon-
taneous proliferative activity within the cambial layer to be
poor and tissue filling of the lesion void incomplete, albeit
occurring to a similar degree for periosteal and peri-
chondrial grafts alike165. Consequently, growth and
differentiation-promoting factors, such as TGF-153,155,156,
have been subsequently incorporated into such treatment
strategies.
Biomechanical stimulatory protocols, such as continuous
passive motion148,149,166, have also been introduced in an
endeavor to boost proliferative and differentiation activities
within the cambial layer. Yet another measure has involved
overlaying the cambial layer with polylactic acid, to facilitate
the spread of repair cells throughout the defect space and,
thus, the extent of cartilage neoformation167. However,
none of these measures has met with very much success.
Clinical experience with human patients has likewise
yielded disappointing results, complete restoration of the
hyaline articular cartilage layer and long-term stability of the
repair tissue formed not having been achieved146,168,169.
Furthermore, several practical problems, such as graft
detachment, are also experienced. Attempts to improvenormal articular cartilage only at defined high-frequency
levels and amplitudes135. Indeed, the experimental set-up
and controls described by van Valburg et al.128,136 appear
to suffer from conceptual deficiencies.
It is highly questionable whether such a drastic measure
as prolonged joint distraction (with all of its associated
risks) is really justified as a therapeutic measure in human
patients merely to relieve pain, even if the arthritic condition
has progressed to such a degree of severity as to render
joint replacement unavoidable.
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have been hampered by technical difficulties. Moreover,
uncontrolled calcification of grafts has been frequently
observed and probably contributes to the high rate of loss.
Despite these problems, symptomatic relief from pain
and improvements in joint functionality have been reported
to be good to very good (50–80%)146,159,169,170, as is
usually the case with surgically-based treatment protocols.
But, regrettably, no prospective, double-blinded, com-
parative clinical trials have been undertaken to assess
whether this type of intervention is more effective than
simpler surgical measures which yield reportedly similar
success rates.
The highly variable outcomes achieved in animal studies
as well as in human patients point to the existence of
fundamental conceptual problems with this treatment
principle. A careful analysis of the biological methodology
employed reveals that the procedure involves the surgical
creation of a full-thickness defect prior to the insertion of a
perichondrial (or periosteal) flap. This step is, of course,
associated with an influx of blood from the bone-marrow
spaces, which seeps into the defect void around the
margins of the graft. Hence, the procedure, when viewed
in its entirety, is really a combined approach, involving
spontaneous repair activity within a blood-derived fibrinous
milieu and a healing response originating from the cambial
layer of the graft. Indeed, it is principally as a consequence
of the former response that repair tissue is laid down at all.
In confirmation of this postulate, and using x- and
y-chromosomes as cell markers, Zarnett and Salter152
have shown about 67% of the repair cells present within
rabbit defects that have received a periosteal flap to arise
from sources other than the graft itself, most likely from the
bone-marrow spaces.
Another factor contributing to the complexity of the
perichondrial/periosteal graft principle is that, physiologi-
cally, the cambial layer abuts on a solid tissue mass
(cartilage or bone), with which it is in mutual signaling
contact. It does not operate like a squamous epithelium,
which produces cells towards an empty space. Trans-
planted perichondrial/periosteal grafts thus lack their
physiological signaling contacts, a circumstance that may
contribute to their poor spontaneous proliferative activity.
New systems need to be developed in which the physio-
logical environment is more closely simulated. This might
be achieved by introducing an appropriate matrix scaffold
containing suitable growth and differentiation factors into
the defect void. By adopting such measures, neoformation
of tissue by the cambial layer and its upgrowth into the
defect void may be achieved, in analogy to postnatal
articular cartilage growth. But if the perichondrial/periosteal
graft is placed on the floor of a defect, as is invariably the
case, the process of chondrocyte maturation will be such
that the largest (i.e., hypertrophic) cells are located near the
articular surface where they will mineralize the surrounding
matrix. A more logical position for the graft would be against
the roof of the defect, with the cambial layer facing down-
ward, in which case, tissue would grow down towards its
floor (preferably through a porous matrix that would
facilitate cell ingrowth and chondrogenic activities). The
structure of the repair tissue thus formed would resemble
more closely that of native articular cartilage. Another
aspect to be considered is that by placing the graft on the
floor of a defect, it acts as a structural barrier and thereby
impedes the angiogenic activities171 necessary for osseous
upgrowth into the bony compartment. In consequence, thegraft will be but poorly anchored. This problem could be
readily overcome by perforating it.
Only when the aspects addressed above have been
systematically investigated in suitable animal models can
we hope to achieve more reliable and reproducible results
in human patients. Experimental data thus far gleaned
using not only autogenic but also cryopreserved allogeneic
grafts172 are of a sufficiently promising nature to justify
continuing efforts with this treatment principle.
Osteochondral transplantation (mosaicplasty)
The idea of implanting chondral or osteochondral tissue
itself within articular cartilage defects dates back to the
beginning of the last century173–175. And this concept still
forms the basis of clinical strategies involving both
autografts176–178 and allografts178–182.
Considering this procedure’s long history, it is surprising
how little laboratory experience has been gained with
autogenic and allogeneic material; especially with auto-
logous osteochondral grafting (mosaicplasty), respecting
which, new surgical instruments have been devel-
oped183,184, both for open-joint and arthroscopic interven-
tions. The few studies performed with experimental
animals185,186 have revealed graft material to persist for
the short-term duration of the follow-up periods, but the
long-term fate of such tissue has not been investigated.
However, one veterinary medical report dealing with
horses187 has revealed that the cartilaginous portion of
the graft survives for a short time only (approximately
6 months), whereas the osseous one becomes integrated
and persists for long periods within the bony compartment.
Despite this situation, there exists a considerable body of
literature pertaining to short-term clinical experience with
this procedure in human patients176,177,179,183,184,188. As
with other surgically-based methodologies, retrospective
analyses have revealed results to be good to very good
(pain relief and improved joint functionality in 60–90% of
cases). But, once again, no prospective, double-blinded
clinical trials have been undertaken to assess whether this
technique is indeed superior to others.
It is a disturbing finding that this intervention has been
applied in human patients before having been thoroughly
tested in animal investigations, particularly long-term ones
which would reveal whether any associated joint path-
ologies develop. In a recent study using sheep189,
mosaicplasty was found to be associated with the rapid
degeneration not only of transplanted cartilage tissue but
also of vicinal native chondrocytes. This latter phenomenon
was attributed to the lack of lateral mechanical support,
since in mosaicplasty, the transplanted tissue cylinders are
held in place only by point-to-point contacts with the sur-
rounding cartilage. In order to prevent tissue degeneration
and unphysiological deformation during the post-operative
phase, lateral support needs to be continuous189, and
achieved using a material that attains at least 80% of the
stiffness of normal articular cartilage. Even theoretically, it
is possible to identify many additional potential problems
with mosaicplasty. In truth, this procedure is doomed from
the onset, since in removing osteochondral plugs from
normal sites of a joint the surgeon is destroying almost as
much healthy tissue as he is attempting to treat that which
is diseased. Neither the donor sites nor tissue opposing
them on the other side of the joint surface have been
subjected to histological analysis, albeit that on the basis
of past experience, both regions would be expected to
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ated after the drilling out of tissue cylinders are indeed
known to undergo significant degeneration52,54. Moreover,
the translocation of tissue from a low-weight-bearing area
to a high-weight-bearing one invariably leads to its degen-
eration, as a consequence of mechanical overloading in the
new position. Mosaicplasty is also associated with unphysi-
ological and injurious tissue compression190, which is
induced when osteochondral plugs are hammered into the
holes surgically excavated for their reception and better
anchorage. But the fate of the diseased tissue intervening
between the graft sites has not been followed. Likewise
awaiting to be investigated is how the procedure affects
congruency between opposing (treated and untreated)
joint surfaces: if poor, this feature could exacerbate the
osteoarthritic condition.
In summary, mosaicplasty is associated with much
potential collateral damage to joint tissue, in view of which
circumstance, the short-term benefits derived by osteo-
arthritic individuals may not justify its performance. With
respect to this procedure, the human patient has been used
as an experimental subject, which is the more unwarranted
in that no prospective clinical trials have been undertaken
to identify unfavorable long-term side-effects.
ALLOGENEIC OSTEOCHONDRAL AND CHONDRAL GRAFTING
Allogeneic osteochondral grafts have been used to fill
articular cartilage defects for several decades, and much
clinical experience has thus been gathered. The approach
does not attempt to induce a cartilage repair response, but
represents a means of substituting failed or lost tissue with
healthy articular cartilage, usually derived from cadavers.
The biological rationale for this approach is based on
the knowledge that osteochondral defects do not heal
and that it is extremely difficult to elaborate a suitable
repair-inducing stimulatory system to promote this process
effectively and in a compartment-specific manner within
both cartilaginous and osseous carrels. It has thus
been deemed simpler to replace the lost tissue volume
with allogeneic material retrieved from cadavers191–193.
Immunological problems are inevitably numbered amongst
the drawbacks associated with this technique194,195.
Nevertheless, patients with large osteochondral defects,
such as those generated by tumor resection, osteo-
necrosis, extensive trauma, broad focal OA or osteo-
chondritis dissecans, have benefited greatly from this
treatment strategy.
A large number of relevant investigations have been
performed using rats195–198. Although cartilage is generally
considered to occupy an immunologically privileged pos-
ition within the joint, these animal experiments reveal that
tissue transplants survive longer under immunosuppres-
sive conditions and also if histocompatibility-matching is
optimized to reduce cell-mediated cytotoxicity and antibody
titre195,196,198. It is also evident from these investigations
that cryopreservation of tissue leads to the death of
chondrocytes, this loss contributing to its deterioration and
reduction in mechanical competence186–201. Fresh tissue
had better structural and mechanical stability as well as a
longer life span than did cryopreserved or lyophilized
material200,201.
Clinical experience with this treatment protocol has been
surprisingly good, immunological reactions being appar-
ently less extensive in humans than in experimental
animals. Human osteochondral transplants also survivefor longer periods (some years), even after freezing or
lyophilization180,181,194,202–204. Success rates range
between 65% and 85%, even after follow-up periods of up
to 10 years192,205–207. Drawbacks associated with this
methodology in the clinical situation include the scarcity of
fresh donor material and problems connected with the
handling and storage of frozen tissue. The small but
ever-present risk of disease transmission must also be
borne in mind.
The success of this long-established methodology could
be further enhanced in the future by improving tissue
cryopreservation and by bringing adverse immunological
reactions under better control.
The use of purely chondral (as opposed to osteochodral)
grafts, such as fetal homografts208 and adult costal
ones209, has not attracted much attention, either experi-
mentally or in the clinical situation. The reasons for this are
two-fold: first, there exist but few sources from which such
tissue can be obtained, and second, it is notoriously difficult
to adequately secure purely chondral tissue transplants
within a defect void, which foredooms them to a high
probability of loss. These circumstances may explain why
scientists and clinicians have not pursued this avenue more
enthusiastically.Tissue engineering
Tissue engineering can be defined as the art of recon-
stituting mammalian tissues, both structurally and function-
ally. Such reconstruction processes can be conducted
either entirely in vitro or partially in vitro and then completed
in vivo, in situ. Success in this technology would obviate the
need for tissue transplantation. And if the appropriate
precursor cell pools could be obtained from embryonic,
fetal or adult allogeneic sources, then the numerous
problems associated with the use of donor tissue would be
avoided. Autologous stem or precursor cells could, of
course, also be employed, but with less facility. Such
engineered material could be used at sites where native
tissue has been lost or compromised by trauma or
pathological processes.
The term tissue engineering is often used quite loosely in
conjunction with any component which, either by itself or in
combination with others, mediates the formation of repair
tissue. Three key constituents usually form the basis of a
tissue engineering approach, namely, a matrix scaffold,
cells and signaling molecules (such as growth factors or
genes). Most of the experience so far gained with this
technique has been derived from in-vitro studies, although
experiments with laboratory animals and humans have also
been conducted. Generally speaking, the approaches
adopted have been of an empirical nature, as will become
apparent in the following subsections.
Many investigators12,210–214 have stated that the tissue
engineering approach is based upon and aims to simulate
embryonic or fetal cell/tissue differentiation processes.
However, the microenvironment within mature tissue, as
well as the adult precursor cell populations available,
preclude such a recapitulation process. Although embry-
onic, fetal and adult organisms share in common the same
signaling substances, the target cells and their reactivity
change during the course of the ontogenic process. Hence,
very basic modifications must be instituted for successful
tissue engineering in adult organisms. The highly complex
nature of this undertaking, as well as promising directions
to be pursued in future endeavors, are discussed under
440 E. B. Hunziker: Articular cartilage repairCOMMENTARY AND PERSPECTIVES after the important




Many different types of matrix have been tested in vitro,
as well as in experimental animals and in human patients,
for their efficacy in facilitating or promoting articular carti-
lage repair. These matrices can be broadly categorized
according to their chemical nature into protein-based poly-
mers, carbohydrate-based ones, artificial materials and
combinations of these (Table I). Even when a naked matrix(i.e., one that carries no cells or signaling substances) is
deposited within an articular cartilage defect, it must be
considered as an information-carrying device and thus as
an active biologic, irrespective of its chemical composition,
physical properties or nature. Such matrices bear biological
information and elicit a biological response within bodily
tissue compartments, which cannot be prevented unless
appropriate modulations are made to guide these in a
direction favorable to tissue repair and integration. The
basic requirements of a matrix to be used in a bio-
logical environment are summarized in Table II (see also
Hunziker215).
Ideally, a matrix should be porous so as to permit either
the migration of loaded cells through its interstices or the
infiltration of native ones from the implant surrounds. Its
surface properties should be such as to promote cell
adhesion, a feature that can be enhanced by coupling the
basic matrix material with specific cell adhesion-promoting
peptides (such as Arg-Gly-Asp)216,217. The material must
also be biocompatible, i.e., induce only minimal adverse
immunological reactions within its destined tissue compart-
ment. In some instances, the matrix may be required to
facilitate or even promote the proliferation of one cell
population whilst inhibiting this activity in another. The
material must also be biodegradable and be capable of
replacement by physiological extracellular components. In
this context, it must be borne in mind that the degradation
products yielded by many matrices have cytotoxic, nephro-
toxic or other undesirable effects. Certain physical charac-
teristics, such as deformability, elasticity and volume
stability must also be satisfied by the matrix. Clearly, it is
not realistic to expect that any one material will fulfill the
entire formidable list of requirements. However, by combin-
ing different types of material and by effecting certain
chemical modifications, we can go some way towards
achieving the ideal.
The value of a naked matrix lies in its ability to enhance
or promote a spontaneous repair response within a defect
whose dimensions preclude this from occurring unassisted
(critical-sized lesions) in a complete and reproducible
manner. When a porous matrix is implanted within the void
of a full-thickness defect, it will soak up and becomeTable I























Geometrical modifications (to produce fibrillar forms or foams)
Matrix combinationsTable II
Matrix requirements
Matrix properties Biological basis
1. Porosity Cell migration
2. Carrier Lodgement and release of signaling substances
3. Adhesion Cell attachment
4. Biodegradability Physiological remodeling
5. Volume stability Smooth surface contour of repair tissue flush with that of native articular
cartilage
6. Biocompatibility Good contact with the native tissue compartment
7. Bonding Enhances interfacial integration between collagen fibrils in repair and
native tissue compartments
8. Internal cohesiveness Prevention of matrix outflow
9. Elasticity Resiliency during and following dynamic or static deformation
10. Structural anisotropy Promotion of native anisotropic tissue organization
Matrix properties specific to the mode of surgical application




B. Stiff and amenable to
press-fitting
Arthrotomy (open surgery of a joint)
(modified after215)
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By this means, a spontaneously developing hematoma can
expand to fill a much larger volume that it would naturally
occupy within an empty space. The process is reminiscent
of the manner in which a drop of ink spreads on a sheet of
blotting paper.
Cells for repair, as well as signaling substances, will
migrate into the matrix together with the blood and thus
form the basis for a spontaneous healing response, which
is supported and enhanced by the implanted scaffold.
Moreover, if appropriate measures are taken to attach this
material to the defect floor and walls, its secondary shrink-
age as a result of blood clot retraction can be prevented,
thereby helping to maximize, reproducibly, the lesion vol-
ume ultimately filled by repair tissue.
Matrix types deemed suitable for articular cartilage repair
purposes will now be dealt with, particular attention being
paid to their biocompatibility. This latter term tends to be
used in rather too loose a sense and should really be
adopted in reference to a specific tissue compartment. An
erythrocyte, for example, is generally considered to be a
perfectly biocompatible cell. But if autologous erythrocytes
are deposited outside the intravascular space, within, for
example, the extravascular connective tissue, they are not
biocompatible with this, but induce a severe inflammatory
response, which is followed by tissue resorption (see
COMMENTARY AND PERSPECTIVES for details). The
same holds true for an autologous fibrin matrix. Hence,
strictly speaking, a biocompatible molecule, cell or matrix is
one that elicits neither cytotoxic effects, inflammatory
responses nor foreign body giant cell reactions within its
destined tissue compartment.
Collagen matrices. Matrices, or sponges, composed of
collagen fibrils have been used experimentally for more
than 20 years. Although such meshworks have been shown
to enhance the spontaneous healing response in rabbit
osteochondral defects218, they have not, as yet, been
employed clinically in human patients (except in cosmetic
facial surgery). They have generally been utilized not
alone, i.e., purely as scaffolds, but as carriers for allogeneic
chondrocytes219–221 or mesenchymal stem cells222 in
rabbits, or embryonic chondrocytes in chickens223, or for
both cells and growth factors224. The size of the defect that
can be repaired using a chondrocyte-collagen composite in
horses has been shown to be much larger than is the case
when no such implant is employed225.
It must be borne in mind that in all of these studies,
defects were osteochondral, i.e., full-thickness, ones.
Hence, any repair activity elicited by the interventions will
have been invariably combined with a spontaneous healing
response, based on the influx of blood-borne cells and
signaling substances from the subchondral bone space.
Indeed, investigations that have addressed the fate of
matrix-borne cells have demonstrated these to constitute
but a small proportion of the final repair tissue population,
those originating from the blood and bone-marrow spaces
by far outnumbering them226.
Unfortunately, biocompatibility issues are only rarely
considered seriously in such studies, adverse reactions
usually being summarily dismissed as minimal or absent. A
more systematic analysis of these aspects undertaken in
our own laboratory has revealed these biocompatibility
problems to be serious. However, collagen is, after all, a
natural bodily constituent whose fibrils furnish a natural
adhesion surface for cells and carry the required biologicalinformation for their activity. Furthermore, the degradation
products of collagen are physiological ones and therefore
non-toxic. Hence, endeavors to improve its biocompatibility,
perhaps by effecting minor structural modifications (the
possibilities for which are numerous), are worthwhile.
Gelatine. Matrices composed of gelatine, which is
basically denatured collagen, have not been used purely as
scaffolding structures to enhance spontaneous repair in
articular cartilage defects. Indeed, even when employed as
carriers, such as for mesenchymal stem cells227, they have
not been widely investigated. However, they have attracted
some attention as a substrate for the support of chondro-
cyte growth, both in vitro227,228 and in vivo227. Gelatine
must be expected to elicit significant inflammatory
responses and foreign body giant cell reactions when
exposed to vascularized tissue compartments, such as
bone and bone-marrow spaces, especially if commercial
products, e.g., Gelfoam®, are employed. This latter
material is indeed primarily indicated for use as a hemo-
static surgical sponge, not as a matrix for carrying cells.
Fibrin. Fibrinogen and its polymerized form, fibrin, are
natural components of the intravascular space, i.e., the
blood, and represent the major extracellular component of
this ‘fluid’ connective tissue. As a polymer unit, fibrinogen
exists physiologically in a liquid state within the blood
stream, being activated to polymerize only in instances of
vascular lesioning or in other pathological situations. It then
forms a three-dimensional solid matrix (fibrin) to prevent
blood loss from the intra- into the extravascular space.
It has no mechanical function but an important inductive
one, in that it facilitates and promotes tissue healing
activities within the extravascular space229,230. Fibrin is
proinflammatory and induces its own degradation and
substitution by cellular components of the extra-
vascular tissue spaces. Its degradation products, being
physiological, are non-toxic.
Fibrin has been employed extensively not only as a
naked scaffolding material but also as a carrier for cells and
growth factors, owing to its ready availability on both an
autologous and an allogeneic basis. Of course, it also plays
a key role in regulating spontaneous repair activities within
full-thickness articular cartilage defects, this circumstance
being put to good effect in surgical strategies employing no
active biologics.
As already discussed, spontaneous healing responses
are confined to defects that fall within a critical size range.
Exogenous fibrin clots, like collagen matrices (see above),
can be used to promote the spreading of endogenous
blood over a larger defect volume than would otherwise be
occupied by the spontaneously developing hematoma, and
thus to reproducibly maximize natural repair activi-
ties231,232. A further improvement has been achieved by
incorporating chondrocytes into the exogenous fibrin clot,
both in vitro233 and in vivo234,235. The healing response
can also be enhanced by including growth factors236, as
shown in equine and canine models for the repair of
articular cartilage237, and in the latter also for that of the
meniscus232,238. However, not unexpectedly (see above),
some immunological reactions to exogenous fibrin have
been observed in several animal studies239,240.
Some investigators have used fibrin glues as a matrix to
enhance articular cartilage repair235,241–243. But owing to
the exceedingly high (unphysiological) concentrations and
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tate cell invasion and thus do not support a healing
response235.
Despite many years of experimental research with fibrin
and some clinical experience in veterinary medicine, this
type of matrix has not been widely employed in human
patients, except for meniscal repair245. Clinicians appear to
have been satisfied with the results elicited by the spon-
taneous healing response, the improvement afforded by
exogenous fibrin in animal experiments having been
deemed insufficiently dramatic or convincing to warrant this
more elaborate approach in humans.
Carbohydrate-based polymers
Polylactic/polyglycolic acids. Polylactic and polyglycolic
acids, both individually and in combination, are manufac-
tured from alpha-hydroxypolyesters246. These polymers
were originally elaborated as surgical suturing materials
(Dexon®)247, but their potential value in cartilage repair
processes has now been under investigation for more than
two decades247–251. Structural modifications to these poly-
mers have yielded fine fibrillar meshworks and foams252,
which have been exploited during the past 10 years for
tissue engineering purposes. These polymers have not
been utilized in their naked form to enhance spon-
taneous articular cartilage repair in situ, probably owing to
their relatively poor cell-adhesion and tissue-integration
properties and their potentially poor biocompatibility.
However, many in-vitro studies have employed these
polymers with a view to engineering cartilage tissue253–256,
perichondrial cells254,257, chondrocytes249,251 or mesen-
chymal stem cells252 having been used for such purposes.
In most of these studies, the influence either of the poly-
mer’s properties, such as its geometry, or of various cell
parameters, such as numerical density, on the quality of the
cartilage tissue engineered were investigated. Although
such engineered constructs have also been tested in
animal models, chiefly in rabbits254,257–260, they have not
been applied in human patients for articular cartilage repair.
There are several possible reasons for this. Firstly, such
constructs are known to induce foreign body giant cell
reactions246,261. And secondly, the polymer substrate
undergoes hydrolytic activity, which yields toxic—partially
cytotoxic—degradation products246. These potentially
deleterious effects have, as yet, not been thoroughly
investigated and thus not excluded.
Agarose. Agarose (sepharose) is a polysaccharide con-
taining L- and D-galactose residues, which is isolated and
purified from certain Asian seaweeds. Its importance as a
matrix for the culturing of chondrocytes, wherein they
express all of their typical gene activities and secrete their
key extracellular components, was first demonstrated 20
years ago by Benja and Shaffer262. Since then, it has been
used in many basic in-vitro studies relating, for example, to
chondrocyte autoregulatory signaling mechanisms263–265
and differentiation from mesenchymal stem cells266, as
well as to extracellular matrix biomechanics267,268 and
calcification269.
The inertness of agarose has rendered it of value in
studying the physiological activities of chondrocytes
in vitro270. But its poor biodegradability in consequence of
this property (owing to the absence of the appropriate
enzymatic degradation systems in mammalian tissues)makes it an unattractive matrix candidate for cartilage
repair studies in vivo. Rahfoth et al.271 have demon-
strated that when agarose is implanted alone within rabbit
knee-joint osteochondral defects, it inhibits spontaneous
repair processes, most probably as a result of extensive
foreign body giant cell reactions to this material within the
bony compartment. This inhibitory response was partially
overcome by incorporating allogeneic chondrocytes into
the agarose matrix. Given the dearth of experimental
animal data relating to the use of agarose in articular
cartilage repair and the poor prospects engendered by its
poor biodegradability, it is of no surprise that this matrix has
not been applied in human patients.
Alginate. Alginate is a gelatinous carbohydrate which is
isolated and purified from brown algae. Polymerization
depends upon the presence of calcium ions, the stiffness of
the resulting meshwork being influenced by its content of
guluronic acid272. It is a matrix that favors chondrogenesis
and the maintenance of chondrocytic phenotypicity in
three-dimensional culturing systems. Alginate has proved
to be useful also in many basic studies relating particularly
to the temporal formation of cartilage matrix, since it can
readily depolymerize (in the absence of calcium ions) and
as promply repolymerize. It is now available in an injectable
form which, when seeded with chondrocytes, is used in the
treatment of vesicoureteral reflux273,274. Within three-
dimensional alginate cultures, dedifferentiated chondro-
cytes can readily redifferentiate if the appropriate
nutrients are supplied275. Likewise, bone-marrow-derived
mesenchymal stem cells can differentiate into chondro-
cytes when seeded within this matrix and under the
appropriate nutritional and stimulatory conditions, both
in vitro and in vivo276. Furthermore, adult human chondro-
cytes cultured within alginate have been shown to synthe-
size cartilage matrix components that bear a close
resemblance to those produced in the native tissue
environment277,278. Despite these favorable indications
in vitro, in-vivo applications of alginate matrices have
yielded disappointing results. When implanted alone,
alginate has been shown to inhibit spontaneous repair
responses279. Likewise, alginate-based cartilage tissue
engineered in vitro induces severe foreign body giant
cell reactions and immunological responses, as well as
itself undergoing degradation, when implanted within full-
thickness defects in experimental animals276,279–281.
Hence, alginate matrices have not been employed in
human patients for articular cartilage repair.
Hyaluronan. Hyaluronan is a physiological component of
the articular cartilage matrix. It forms macromolecules of
tremendous length and molecular weight which are per-
fectly biocompatible and biodegradable (for review, see
Goa et al.282). In theory, hyaluronan would be an ideal
matrix to support articular cartilage repair if it could be
implanted in an unmodified form. But in order to achieve the
physicochemical properties and structural organization
requisite for this purpose, it is usually cross-linked
by esterification or other means282. And as a result, its
biocompatibility is compromised283.
Matrices composed of hyaluronan have not been applied
alone to enhance spontaneous repair responses, but they
have been frequently used as carriers for chondro-
cytes284,285 or bone-marrow-derived mesenchymal stem
cells286,287. Hyaluronan matrices loaded with such cells
have been shown to elicit the deposition of a cartilage-like
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of this occurring also in vivo285,288–290. Such constructs
have likewise been shown to support cell differentiation
processes291. However, the hyaluronan degradation
products yielded may lead to chondrolysis under certain
conditions292.
In an unmodified form, hyaluronan has proved to be an
unsuitable matrix. Only modified (i.e., cross-linked) ver-
sions have found a use in articular cartilage repair, and
these are poorly biocompatible and chondrolytic. Hence,
until further chemical modifications can be elicited to pro-
duce a more functionalized derivative293, this type of matrix
is unlikely to be used in human articular cartilage repair.
Chitosan. Chitosan (polyglusam) is a copolymer of
glucosamine and N-acetylglucosamine, which may be
cross-linked with polyanionic chondroitin-sulfate to form a
hydrogel294,295. Several in-vitro studies yield evidence of
its potential value as a matrix to facilitate articular cartilage
repair. It efficiently supports not only chondrogenic
activities295–297, but also the in-vitro expression of cartilage
extracellular matrix proteins by human chondrocytes294. It
can also serve as a carrier for growth factors298. Chitosan
has not yet been employed as a matrix in animal or human
articular cartilage repair studies, its sole clinical use thus far
having been to prevent post-surgical adhesions299. But
these are early days. And as investigators become more
aware of this material, it is likely to be adopted with greater
enthusiasm, owing to its excellent biodegradability.
Synthetic polymers
Carbon fibers. Meshworks composed of carbon fibers
have been used for more than two decades300 in ortho-
pedic tissue engineering. Although chemically inert, such
fibers can nevertheless carry non-biological, alien informa-
tion to bodily tissues. Hence, not surprisingly, when
implanted within full-thickness articular cartilage defects,
carbon-fiber meshworks elicit substantial foreign body giant
cell reactions and immunological responses; these adverse
activities can extend even to the synovium, where they
induce synovitis300–303.
Carbon-fiber meshworks have been applied in several
laboratory animals, such as rabbits300,303–308 and guinea
pigs309, with a view to enhancing and spatially expanding
the extent of the spontaneous repair reaction within full-
thickness articular cartilage defects. Reported data reveal
the healing response to embrace a larger volume of the
lesion void than in untreated cases but with no improve-
ment in the quality of the repair tissue formed, this being
mainly of a highly-vascularized fibrous type with poor
biomechanical properties.
Despite these unpromising results in experimental
animals, carbon-fiber meshworks have nevertheless been
applied in human patients, with unsurprisingly mixed
success. Some clinicians have obtained good to excellent
results (pain relief and improved joint functionality in
70–80% of cases), mainly in young individuals (20–40
years of age)310,311, whereas others report less encourag-
ing ones, with success rates of no more than 41%301,302.
Regrettably, no propective, double-blinded clinical trials
have been undertaken to clarify this nebulous picture.
Improved results with this type of meshwork could possibly
be elicited by coating the carbon fibers with hyaluronan
and incorporating chondrogenic cells into the resulting
matrix312.Dacron and teflon. Meshes composed of dacron (poly-
ethylene terephthalates) or teflon (polytetrafluoroethylene),
like those consisting of carbon fibers, have been applied in
experimental animals with a view to enhancing and
spatially expanding the extent of the spontaneous repair
reaction within full-thickness articular cartilage defects.
When tested in rabbits313–315, such matrices have indeed
elicited a considerable increase in the volume of the lesion
void filled with repair tissue, but the composition of this was
very variable, ranging from a highly-vascularized fibrous
type of connective tissue to fibrocartilage. These materials
have also been used to replace meniscal tissue in rabbits,
with satisfactory results314,316,317.
With respect to the use of these materials in human
patients, one study reports on the application of
polyurethane-coated teflon meshes318. Pain relief and
improved joint functionality lay within the usual range (i.e.,
70–80%), although a higher incidence of joint stiffness was
encountered within this patient population.
When applied, for example, as suturing materials,
artificial ligaments or membranes for abdominal surgery,
dacron and teflon are known to elicit severe foreign body
giant cell reactions and inflammatory responses, which
would likewise be expected to occur in full-thickness osteo-
chondral defects. This may be one of the main reasons why
the testing of such matrices has not been pursued with
greater vigour by scientists. Indeed, unless novel and more
functionalized derivatives can be produced henceforth,
these materials are unlikely to attract much attention in the
future.
Various other matrices
A number of other experimental matrices are currently
under development, or have been available for a while but
cannot be recommended for veterinary or human use until
certain serious problems have been solved. Included in the
latter category is the hydrogel, polymethylmethacrylate,
which was first proposed for use in articular cartilage repair
8 years ago319,320. Hydrogels are a class of water-swollen
hydrophilic monomers which are cross-linked around a
linear reinforcing polymer network. Their mechanical prop-
erties can be modulated by changing the nature of the
individual monomer units, examples of which include poly-
urethane, acryloilmorpholine, N,N-dimethyl acrylamide,
N-vinyl pyrrolidone and tetrahydrofurfuryl methacrylate.
The numerous design possibilities, which relate, for
example, to the control of matrix swelling and hydration,
stiffness and porosity321–324, render these hydrogels very
attractive. Bovine chondrocytes have been shown to
remain viable when cultured on one such hydrogel325, and
some promising results have been obtained when these
materials have been implanted within rat articular cartilage
defects326. However, the matrices thus far elaborated are
but poorly biocompatible, and their very limited bio-
degradation yields potentially toxic products. Hence, further
substantial improvements in these hydrogels are still
required.
Novel matrices composed of hydroxyapatite, whose
porosity and density can be varied, have been introduced
and already tested in full-thickness articular cartilage
defects, either in a pure form or coated with other
materials314. Chondrocytes have been shown to bind to the
surfaces of such matrices in vitro327,328 and to be able to
partially degrade it329, but animal experiments undertaken
with hydroxyapatite330 have yielded conflicting results331.
444 E. B. Hunziker: Articular cartilage repairIn goats, it was found to be an unsuitable matrix for
supporting articular cartilage repair331. Indeed, when
placed within the hyaline articular cartilage compartment,
hydroxyapatite is clearly in an unphysiological (ectopic)
situation330.
Polyurethane has been recommended as a matrix to
support meniscal repair and replacement318,332–335. But
its biocompatibility and biodegradability are so limited as
to render it of little value unless combined with other
materials336. Indeed, its degradation products elicit very
serious side-effects within the joint cavity and cause severe
irritation of the synovium.
Polymers of butyric acid are currently being investigated
as possible matrices for articular cartilage repair. Chemical
changes therein permit modifications in, for example,
fibril structure, density and porosity, which render them
attractive potential candidates. However, butyric acid itself
carries much information within a biological environment,
such that it is poorly biocompatible. Its biodegradation
is also very limited and yields products that elicit
undesired side-effects. It also affects resident cell
populations337, inhibiting their growth and kinetic activi-
ties338,339, suppressing protein secretion340 and inducing
apoptosis341,342.
Polybutyleneterephthalate cross-linked with either poly-
ethylene oxide or polyethylene glycol (Polyactive®) has
also been suggested as a potential matrix for use in
articular cartilage repair343. A number of basic studies
pertaining to the biomaterial properties of this material have
been conducted344–347 and yielded promising data
respecting its production as either a liquid, fibrillar mesh-
work, foam or microspheres, with various porosities. In-vivo
testing in animal defect models has been very limited347,
but preliminary data look encouraging348.
Matrix combinations and chemical modifications
The possibilities for chemical modification to the basic
matrices described above are almost endless. Combina-
tions of more than one matrix type349, the formation of
copolymers, and cross-linkage with various substrates to
modify three-dimensional organization and geometry are
also feasible. In the present article, only a few of the more
promising examples will be dealt with. It must also be borne
in mind that most of the materials under development have
as yet been tested only in vitro, using cultured cells for
cytotoxicity tests.
One very popular approach has been to cross-link
matrices, for example, collagen-based ones36,350,351. The
cross-linkage or functionalization of hyaluronan-based
matrices has also been suggested to improve their utility in
articular cartilage repair289,293. Likewise, very promising
results have been achieved by forming copolymers
between different chemical species, such as collagen and
alginate352 or polyurethane and polylactic acid336. The
functionalization of a matrix by incorporating either agents
to promote cell adhesion353 or growth factors354,355—
whereby it serves as a delivery system—is also a very
promising approach to improving its performance in articu-
lar cartilage repair. Geometrical modifications too, elicited
by the production of sponge- or foam-like matrices252, have
been shown to enhance the differentiation potential and
metabolic activity of chondroprogenitor cells and mature
chondrocytes, respectively.CELLS IN SUSPENSION
The concept of using transplanted cells for articular
cartilage repair is an old one, the underlying rationale being
to supply the defect site with a homogeneous population of
chondrocytes that would produce an optimal and enduring
cartilage matrix.
In the 1980s, chondrocytes, as well as chondroblasts,
were first used for transplantation purposes356–360, but
always embedded within a matrix. The idea of transplanting
autologous chondrocytes suspended at low densities in
culture medium was propounded as a purely empirical
approach by Grande et al.226 and initially tested in the
clinical situation by Brittberg et al.310. There exists no
experimental evidence to justify this approach, since
dedifferentiated chondrocytes have never been shown to
undergo redifferentiation, either in two-dimensional cultur-
ing systems262,361 or in aqueous suspension362, except
under high-density micromass conditions363,364; only in
three-dimensional systems, i.e., within a matrix. The use of
chondrocytes in a dedifferentiated (i.e., fibroblast-like) form
is necessary for their in-vitro expansion over two or three
generations, which, in turn, is required to yield the high
numbers called for to fill the large defect volumes; albeit
that in native articular cartilage, the cellularity is exceed-
ingly low (approximately 9′000 chondrocytes per mm3 of
tissue, i.e., a volume density of 1.5–2%)365. The cell
suspensions are introduced into shallow, full-thickness
defects, and their loss into the joint cavity claimed to be
prevented by covering the lesion with a periosteal flap. This
is sutured, cambial layer downwards, to the surrounding
articular cartilage and may be additionally secured by
means of fibrin glue or an alternative adhesive310,359,360.
The application of this methodology in rabbits366–368
results in the formation of fibrocartilage-like repair tissue.
However, a close scrutiny of the experimental approach
reveals a number of problematic aspects. To begin with, the
periosteal flap (250 m in thickness) occupies approxi-
mately 85% of the height of the cartilage defect void
(300 m) in rabbits215. Hence, the lesion is filled predomi-
nantly with this tissue from the very onset of the exper-
iment. The true origin of the repair tissue subsequently laid
down is unknown. If the periosteal flap remained in place,
then one would encounter a dense, fibrous connective
tissue, which is not the case. In only one study has the
fate of the transplanted autologous chondrocytes been
monitored226. In this, they were found to represent
maximally 8% of the repair cell population. The origin of the
overwhelming majority was not elucidated, but the
subchondral bone-tissue space represents the likeliest
source, as in the case of spontaneous repair responses.
Indeed, the autologous chondrocyte principle has since
been challenged and disproved by Breinan et al.369 Using a
canine model, these authors demonstrated that the trans-
planted dedifferentiated chondrocytes did not contribute to
the repair response. Although such cells could, in theory,
adhere to the floor and walls of a defect, they are unable,
even then, to form cartilage tissue262,361. And in a recent
report370, sutured periosteal as well as other types of
flap were shown to become detached within a few days
of surgery unless appropriate measures were taken to
immobilize the affected joint. The implication of this finding
is that the periosteal flaps used to trap autologous dediffer-
entiated chondrocytes within the defect void are lost
together with these within a matter of days following sur-
gery and that thus neither this tissue nor the transplanted
cells contribute to the repair response. This interpretation
Osteoarthritis and Cartilage Vol. 10, No. 6 445accounts for the findings reported by Breinan et al.369,
which revealed no differences in the repair responses
manifested by treated and untreated defects.
Another aspect that complicates the interpretation of
findings relating to the autologous chondrocyte transplan-
tation approach is that, even theoretically, it represents not
a single but potentially a triple chondrogenic system, in that
repair responses may originate from (1) the transplanted
cells (highly unlikely), (2) the cambial layer of the periosteal
flap, and (3) the subchondral bone-tissue spaces (spon-
taneous healing on the basis of blood-clot formation).
Which of these sources is the prime contributor is still
unclear. But the spontaneous response mediated by blood-
clot formation is the likeliest candidate, since the periosteal
flap (when not detached) will help to keep the developing
hematoma in situ and, by itself imbibing blood flowing in
from the subchondral bone-tissue spaces, will serve to
increase the defect volume permeated by this fluid, thereby
maximizing the extent of the repair response. That the
periosteal flap contributes actively to the repair response is
unlikely (see Perichondrial/periosteal grafts), although its
position on the roof of the defect would yield a more
physiologically structured type of repair cartilage than
ensues when it is lodged on the floor of the lesion (see
section Perichondrial/periosteal grafts). Hence, the auto-
logous chondrocyte transplantation approach merely repre-
sents an alternative (though more complicated) version of
surgical strategies involving no active biologics that are
instigated to enhance spontaneous repair responses.
Despite the unclarity associated with this approach, it
has nevertheless been introduced into clinical practice.
Brittberg et al.310 have applied the autologous chondrocyte
implantation principle in human patients with reportedly
good to excellent results (pain relief and improved joint
functionality in 60–90% of cases). Similar findings have
been reported by other investigators (for review, see
Gillogly et al.)368. A retrospective clinical study performed
by Peterson et al.371 has confirmed the success rate to lie
between 65% and 90%. But no prospective, double-
blinded clinical trials have been undertaken to compare
this methodology with alternative, well-established and
less-expensive treatment protocols.
CELLS IN A MATRIX-CARRIER SYSTEM
There exist a number of chondroprogenitor cell pools
within adult mammalian organisms that have the potential
to differentiate into chondrocytes and thus form cartilage
tissue, and that can be used for transplantation purposes.
These include those within the cambial layers of the peri-
chondrium and periosteum, adult cartilage itself (chondro-
cytes), the bone-marrow stroma (mesenchymal stem cells)
and the synovial membrane. Fetal and embryonic precur-
sor cells, such as fetal stem cells and chondroblasts, can
also be employed. During the past few decades, many
empirical approaches have been introduced to test the
usefulness of these various cell pools in inducing a repair
response within articular cartilage defects, and these will
now be appraised. Such cells have always been trans-
planted within a matrix-carrier system and invariably tested
in full-thickness articular cartilage defects. Hence, this type
of approach has always been superimposed upon a spon-
taneous healing response originating from the subchondral
bone-tissue spaces. It must likewise be borne in mind that
blood seeping into the defect void carries not only a variety
of cell types but also a whole spectrum of ill-definedsignaling molecules, which most probably play an import-
ant role in triggering the chondrogenic switch. These cell–
matrix transplantation strategies must therefore be
considered as potentially dual chondrogenic systems, the
transplanted one involving no intrinsic signaling regime
wherewith to better control the chondrogenic outcome, as
will be discussed under CELLS, MATRICES AND SIGNAL-
ING MOLECULES.
The transplantation approaches described below are still
at experimental phases of investigation and have not yet
been applied in clinical practice. The appraisal will thus be
confined to descriptions of the biological principle as well as
to basic scientific criticisms and suggestions for possible
improvements.
Chondrocytes and chondroblasts
Embedded within a collagenous matrix, chondro-
cytes of both autogenic226,372 and allogeneic
origin219,220,357,362,373–376 have been tested. Other
matrices used as carriers for allogeneic chondrocytes
include fibrin234,377, carbon fibers378 and agarose271. In
some studies, fetal or embryonic chondrocytes or
chondroblasts have been employed223,356. In each
instance, authors reported an improvement in the healing
response elicited by the treatment: the repair tissue gener-
ated was mainly fibrocartilaginous in nature and filled a
greater volume of the defect void than did that laid down
within untreated control lesions. The transplanted chondro-
cytes or chondroblasts were concluded to have a beneficial
effect on the spontaneous repair response, over and above
that elicited by the matrix itself. However, the long-term
stability of the tissue formed has been questioned219,
which is not surprising given the incompleteness of
the cartilage tissue differentiation process373. Moreover,
immunoreactivity towards the transplanted constructs has
also been described240. As already mentioned, such cell–
matrix constructs have not been applied clinically in human
patients.
Perichondrial/periosteal cells
The chondrogenic potential of certain perichondrium-
derived and periosteal cells has been known for several
decades140,141,379–381. They reside within the cambial
layer (i.e., within the proliferative stratum) of the perichon-
drium and periosteum, respectively, and have been iso-
lated from both autogenic and allogeneic sources for tissue
engineering purposes. Following appropriate in-vitro testing
for their chondrogenic potential382–384, perichondrial and
periosteal cells have been embedded within various
matrices, including those composed of polylactic
acid257,385. Perichondrial cells of autogenic origin have
been found to perform better than those derived from
allogeneic sources258,259.
Following implantation in experimental animal defect
models, such cell–matrix constructs have been shown to
appreciably enhance the articular cartilage healing
response. However, these perichondrial and periosteal
cells do not appear to survive for long periods within the
repair tissue formed, their numerical density undergoing a
continual decline with time386. Local recruitment of cells
from the bone-marrow and osseous-tissue spaces partially
offset these losses, but without benefitting the long-term
stability of the repair tissue.
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humans would be of great advantage, owing to their high
proliferative potential and capacity to differentiate into
chondrocytes, irrespective of the age of the donor383, this
type of cell–matrix construct has not been applied in the
clinical situation. The highly variable results achieved in
experimental animals, as well as the long-term instability of
the repair tissue formed and immunoincompatibility prob-
lems with allogeneic cells386, may have contributed to this
circumstance (although such difficulties have not deterred
investigators in other instances). However, the clumsiness
of the approach (involving two surgical interventions and
complicated cell isolation procedures), as well as the
absence of a simplified, commercially supported strategy,
are more probably accountable.
Stromal cells of the bone marrow
That the bone-marrow stroma contains multipotential
precursor cells has been known for some time387–390, but a
keen interest in them did not become manifest until the
early 1990s106,391, since when their multipotent lineage
capabilities have been identified and better character-
ized108,392,393. The great value of these cells for tissue
engineering purposes lies in their pluripotency; their weak-
nesses are that their numbers decline, and their potential to
proliferate and differentiate deteriorate, as a function of age
in humans106,391,394,395.
Mesenchymal stem cells of bone-marrow stromal origin
have been applied with a view to inducing articular cartilage
repair in various animal models222,396,397 and in conjunc-
tion with different matrices, such as collagen-type-I gels398
or modified hyaluronan288. Although numerous in-vitro
studies have been undertaken to follow the course of
mesenchymal stem cell differentiation and to assess
the influence of growth factors on the direction
pursued364,399–403, in-vivo experiments have been con-
ducted in the absence of exogenous signaling substances.
It has been left up to Nature to supply these, although
Lennon et al.397 have deemed it advantageous to incorpor-
ate fibroblasts into their system in order to enhance tissue
differentiation.
Overall, the results achieved using bone-marrow stromal
cells have been similar to those yielded using other cell–
matrix systems, the repair tissue formed having been
principally fibrocartilaginous in nature, but of variable qual-
ity and durability. One advantage gained by using such
cells is that, owing to their stem-cell-like properties, they
are fairly well tolerated immunologically. Hence, allogeneic
cells could be made readily available on a commercial
basis, which would obviate the need for bone-marrow
tissue biopsies of the iliac crest, whence autologous cells
would be derived in individual patients. The undertaking
would not only eliminate the risk of inducing potentially
long-lasting secondary pathologies at this site, but
also solve sterility problems and logistic issues relating to
transport.
In one instance, this type of cell–matrix construct has
been applied in humans, but using bone-marrow stromal
cells of autologous origin404.
Synovial cells
Studies relating to the ontogenetic development of
synovial joints have revealed articular cartilage chondro-cytes and synovial cells to originate from a common
precursor pool (for review, see Pacifici et al.)405 and to exist
in a close functional relationship not only during
fetal development but also in adult life406. Under various
pathological conditions pertaining in-vivo, synovial cells
have been shown to possess tremendous chondrogenic
potential407–410, even within chondromatous tumors of the
synovial space and chondroid osteophytes411–415. Further-
more, human chondroprogenitor cells of synovial
origin416,417 have been demonstrated to sustain their high
proliferative potential and capacity to differentiate into
chondrocytes irrespective of the individual’s age.
Chondroprogenitor cells of synovial origin have, as yet,
not been isolated for use in articular cartilage repair
studies. However, in a series of in-vivo experiments con-
ducted with adult rabbits, miniature pigs and goats418,419,
synovial cells have been indirectly shown to be recruited for
the repair of small partial-thickness defects, provided that
an appropriate matrix containing the necessary growth
factors (of the TGF- superfamily)418 to induce their
proliferation, migration and differentiation, is furnished.
With respect to larger partial-thickness defects, the
methodology would need to be adapted to accommodate
the circumstance that such lesions take longer to heal
(Hunziker et al.: unpublished data). In the case of full-
thickness defects, measures would be required to
prevent osseous upgrowth into the cartilaginous
compartment171,215,420,421.
When the body of data obtained using various cell types
in conjunction with different matrices is viewed overall, it
becomes abundantly clear that in no instance have the
findings been conclusive. In most cases, this circumstance
reflects poor study design with the omission of essential
controls. Empty, untreated defects do not suffice in this
respect. In only a few instances has the matrix itself been
tested alone, albeit that this is an absolute requirement.
And particularly so since, as revealed in this review, avail-
able matrices generally have suboptimal biocompatibility
and biodegradability properties, and must therefore be
expected to elicit adverse reactions which need to be
overcome during the course of healing. The transplanted
cells may help in such a situation, but this needs to be
proved experimentally. The specificity of the cellular effect
must likewise be confirmed, using an alternative cell type
as a negative control. But in none of the reported studies
have inert control cells been tested. Furthermore, instead
of resorting to the usual subjective, semi-quantitative
histological analyses, investigators should adopt rigorous
morphometric approaches422–424 involving unbiased,
systematic random-sampling protocols425.
CELLS, MATRICES AND SIGNALING MOLECULES
The current trend in tissue engineering is clearly towards
the elaboration of constructs that consist not only of a
matrix and cells but also of signaling molecules to specifi-
cally guide the course of differentiation in the desired
direction. One of the reasons for this is the emerging
realization that durable, high-quality, hyaline-like articular
cartilage repair tissue can be formed on a reproducible
basis only if the healing response is streamlined: firstly by
implanting a more homogeneous population of cells; and
secondly, by inhibiting the ‘contaminating’ spontaneous
repair reaction, which involves the uncontrolled activities of
numerous cell types and signaling substances originating
from the subchondral bone-tissue spaces.
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can be adopted. According to the first, repair tissue is
engineered completely in-vitro, the fully-differentiated con-
struct being then implanted within the defect void. Its
advantage is that cell metabolism and differentiation are
subject to better control in-vitro than in-vivo, provided that
the appropriate bioreactor systems, growth factors and
delivery systems are available. Its drawbacks are that
problems associated with repair tissue integration and
mechanical fixation cannot be readily anticipated and
solved. Moreover, the appropriate mechanical loading con-
ditions are difficult to simulate in-vitro; hence, the com-
position of the extracellular matrix may not be ideally suited
to the specific needs of the prospective repair site. Further-
more, biocompatibility and immunological problems are
frequently associated with this approach. And given the
natural curvatures of the joint surfaces, the press-fit implan-
tation of such engineered implants poses another great
challenge which remains to be solved.
The second approach, which is more frequently adopted,
aims to engineer only the basic building block, namely, a
matrix scaffold containing a homogeneous population of
cells and signaling molecules entrapped within an appro-
priate delivery system, to ensure that the desired differen-
tiation process takes place in-vivo and to assure the
long-term maintenance of chondrocytic activity within the
repair tissue formed. According to this approach, the differ-
entiation and remodeling of repair tissue occurs in-vivo
under physiological conditions of mechanical loading.
Repair tissue formed in situ is more likely to adhere to, and
integrate with, native articular cartilage than is that pro-
duced in-vitro, and it will also adapt naturally to the con-
tours of the synovial joint. One of the disadvantages of this
approach is that cell activity is more difficult to control on a
long-term basis. Moreover, appropriate measures must be
taken to prevent ‘contamination’ from cells and signaling
substances involved in the spontaneous healing response,
since the tissue thereby formed would compromise the
quality and mechanical competence of the final repair
composite.
Thus far, engineered constructs produced according to
either of these approaches have been tested only in-vitroand using experimental animals. Illustrative examples of
studies involving each approach will now be furnished,
preference being given to those that embrace the current
trend in articular cartilage repair to use a matrix scaffold, a
homogeneous population of cells and appropriate signaling
molecules.
Before embarking on a particular tissue engineering
approach, both the investigator and the clinician must
decide which type of defect they ultimately wish to treat,
since the biology of the surrounding microenvironment is of
paramount importance in determining the long-term suc-
cess or failure of the implanted material. It must therefore
be clear from the outset whether constructs are destined
for partial- or full-thickness defects. In the former case,
cell ‘contamination’ from the blood vasculature as well
as from the bone-marrow and osseous-tissue spaces can
be excluded, whereas in the latter, such influences are
ever-present and must be brought under control.
The engineering of fully-mature cartilage constructs
in-vitro has been described by a number of authors426–429.
But, owing to the aforementioned problems of immuno-
logical rejection, mechanical fixation, tissue integration and
inadequate physical properties, very little success has
been achieved in experimental animals427,430. And whilst
scientists are still struggling with these basic difficulties429,
very little progress is likely in the near future. Hence, the
clinical application of such constructs in human patients
seems to be a long way off.
The usefulness of different signaling substances, i.e.,
growth factors, in inducing chondrogenesis has been
evaluated mainly in-vitro and to only a limited degree in
vivo. Recent reviews covering this field have been
written by Reddi et al.29,431,432, Glowacki433 and van den
Berg434. In-vitro experiments have involved various combi-
nations of matrix, cell type and growth factor, such as
collagen matrices containing bone-marrow stromal cells
and TGF-1435,436, agarose matrices containing chondro-
cytes and FGF-2437, fibrin matrices containing chondro-
cytes and IGF-1236, and polylactate matrices containing
perichondrial cells and TGF-1233,384. Successful testing
in-vivo has been achieved using horse237 and mature
miniature pig models (Fig. 1)438. These latter studies serveFig. 1. Light micrographs of knee-joint articular cartilage in mature Goettingen miniature pigs. (a) Normal articular cartilage tissue (AC)
together with the underlying layers of calcified cartilage (CC) and subchondral bone (SCB). (b) Partial-thickness defect (D), 2 months after
treatment with chondroitinase AC and application of a fibrin matrix containing both free (4 ng/ml) and liposome-encapsulated (600 ng/ml)
TGF-1. It is filled with repair tissue which has a cartilage-like appearance. Cells have undergone transformation into chondrocytes, but are
more isotropically distributed and present at a higher numerical density than those within the surrounding native tissue. A gradient in cell size
and shape is nonetheless apparent. Chondrocytes in the superficial region are small and spindle-like, whereas those in deeper zones are
larger and have an oblate spheroid form. The cells have laid down a matrix which stains somewhat less homogeneously than that of native
tissue, indicating that it is not truly hyaline, but rather fibrous, in nature. At the defect borders (DB), repair and native tissue are well
integrated. A,B: 120-m-thick polished saw-cuts, surface-stained with McNeil’s tetrachrome/Toluidine Blue O/basic Fuchsine. Bars=100 m
(modified after438).
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in-vitro one. Under in-vitro conditions, various types of
growth factor have been shown to support chondrogenic
activities434, whereas in vivo, principally only those of the
TGF- superfamily are effective.
Gene therapy and gene transfer technologies also offer
potent new possibilities for managing articular cartilage
repair responses, the subject having been recently
reviewed by Evans13,439,440 as well as by other
authors441,442. In vitro, genes carrying chondrogenic infor-
mation have been successfully transfected into chondro-
genic precursor (bone-marrow stromal) cells443,
chondrocytes444,445, perichondrial cells444 and periosteal
ones446. In vivo, a successful attempt to induce a repair
response using transfected mesenchymal cells or chondro-
cytes has been reported by Gelse et al.447 This latter study
demonstrated that the transfected cells could furnish suffi-
cient quantities of BMP-2 to induce cartilage tissue forma-
tion whilst avoiding inadvertent vector spreading or
immunological reactions.
COMMENTARY AND PERSPECTIVES
An overview of the tissue engineering literature relating
to articular cartilage repair reveals the approaches thus far
pursued to have been principally of an empirical nature and
still very much at an experimental stage of development.
Results achieved to date are far from satisfactory with
respect to repair tissue quality and durability. Success in
the future depends upon our now following a more rational
approach to the problem, based on biological principles
at the molecular, cell and physiological levels. Tissue
engineering cannot be viewed simply as a recapitulation of
embryological differentiation processes, as is frequently
suggested11,29,432, since the cellular microenvironment and
tissue contextualities encountered in adult organisms are
fundamentally different from those pertaining in embryo-
logical ones. Apart from the signaling substances, which
are most probably the same, every other component is
different, including the existence of an active immune
system in fully-developed organisms.
Our aspiration to engineer an ideal construct in-vitro,
consisting of a matrix, cells and signaling substances,
which would undergo terminal differentiation in situ to yield
a perfectly well incorporated and durable type of hyaline-
like articular cartilage repair tissue may be overly optimistic,
especially when we consider the mammalian body’s own
limited tissue engineering capacity, as exemplified in scar
formation. If a lesion is created within the subcutaneous
tissue of a rat and then filled with ‘perfectly biocompatible’
cells, such as autologous erythrocytes (Fig. 2), or with a
‘perfectly biocompatible’ matrix, such as autologous fibrin,
these elements are neither directly incorporated nor directly
transformed into scar tissue. Rather, they are initially met
by a sterile inflammatory response which is followed by
their resorption and replacement with vascularized scar
tissue (Hunziker et al.: unpublished data). The implication
of these findings is that biocompatibility is not a generalized
bodily phenomenon but a tissue (compartment)-specific
one. With this knowledge comes the realization that tissue
engineering must be broached with a fresh outlook. In the
future, it will be necessary to aim at manufacturing a
construct that will be accepted by, and become integrated
with, tissue neighboring its destined site without triggering
the immunological responses that would result in its resorp-
tion. Following resorption, it would inevitably be replaced byVarious repair-associated issues
CHONDROCYTE LOSS
Surgical undertakings such as debridement, shaving,
laser abrasion and tissue-edge verticalization (performed
to improve the fitting of an implant), embrace, in most
instances, ‘healthy’ articular cartilage surrounding the
lesion site. The removal of such tissue is associated with
cell apoptosis and/or necrosis along the cut sur-
faces27,53,54,56. Given that the cellularity of articular carti-
lage tissue is in any case very low and that the surviving
vicinal chondrocyte population does not compensate meta-
bolically for the loss of its neighbors55, these effects—
which are iatrogenic—can be expected to create a biologi-
cally unfavorable environment for an implanted construct.
LOSS OF FLAPS
In a number of investigations involving animal models,
as well as in clinical orthopedic practice, periosteal flaps
are sutured to the hyaline articular cartilage borders of
defects containing cell suspensions whose loss they are
deemed to prevent226,310,366,369. In a recent study, how-
ever, such flaps have been shown to detach following
surgery unless measures are taken to immobilize the
affected joint, the delamination rate being almost 100%370.
It is thus essential to monitor the fate of these flaps during
the post-operative healing phase using high-resolution,
in-vivo imaging technologies.Fig. 2. Light micrograph of autologous red blood cells (RBCs) 10
days after deposition within the subcutaneous tissue of an adult
rat. A very active resorption front is apparent on the left-hand side
of the picture, neutrophils and macrophages being present in
abundance. This finding indicates that the autologous erythrocytes
have elicited a very considerable inflammatory response. 5-m-
thick, paraffin-embedded section stained with hemotoxylin-eosin
(Hunziker, unpublished data).a scar-like or fiber-rich tissue bearing little resemblance to
the hyaline-like articular cartilage type to which we aspire.
Viewed in another light, if the engineered constructs are to
be merely resorbed and exchanged following their implan-
tation, then the great pains to which investigators are put to
consummate a combination of constituents and conditions
conducive to cartilage tissue formation in-vivo will be in
vain.
Fig. 3. Schematic representations of like-sized defects superimposed upon light micrographs of (a) human, (b) goat and (c) rabbit articular
cartilage tissue (together with varying portions of the underlying subchondral bone), represented at the same magnification. Because the
height of the articular cartilage layer in humans is several times greater than that in goats, and many times more so than that in rabbits, the
biological environment surrounding each defect differs. In the human, the defect is a partial-thickness one, and, as such, it is surrounded
exclusively by cartilage tissue. In the goat and rabbit, lesions of the same dimensions are full-thickness ones; approximately 85% and 95%
of their volumes, respectively, being surrounded by osseous tissue and bone-marrow spaces. In these two latter cases, bleeding from the
bone-marrow spaces will furnish the defects with an abundant supply of cells and signaling substances to which the human partial-thickness
one will not be accessible (modified after215).
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The poor integration of repair tissue with native articular
cartilage is a problem that has been recognized by several
authors36,189,438, and is one that must be resolved if we are
to achieve enduring healing results and biomechanical
competence. Various measures have been employed to
promote this process by establishing good contact between
implants and native articular cartilage, including the use of
collagen cross-linkers36, biological glues (e.g., tissue trans-
glutaminase84) and other adhesives359,448. Another poss-
ible approach that has been shown to have a beneficial
effect is the brief enzymatic degradation of proteoglycans
along defect surfaces41, these molecules being known to
impede both cell and matrix adhesion360,449–451.
MECHANICAL FACTORS
The role of mechanical factors in determining repair
tissue quality has been recognized for some time35,452,453,
the outcome having been shown in a number of animal
experiments to be improved by intermittent active or con-
tinuous active/passive motion148,149,454–456. Not surpris-
ingly therefore, physical parameters have been identified
as being of the utmost importance in tissue engineer-
ing268,457, albeit that the mechanisms whereby such
factors are transmitted to cells remain largely unknown,
although under current investigation458. Hence, in human
clinical practice, post-operative care and physical
therapy will most probably play not inconsiderable roles in
determining the healing outcome.
THE SCALE OF TISSUE REPAIR
Investigators pay too little heed to the dimensional
aspects of articular cartilage repair. What volume needs to
be filled with repair tissue? Can the biologics of the engi-
neered construct cope with this? Such simple questions—
though of utmost importance—are rarely addressed in
reported tissue engineering studies. Even just a casual
glance at the respective histologies of knee-joint articular
cartilage in humans and experimental animals commonly
used for the testing of repair concepts (Fig. 3) reveals very
obvious differences, not only in structural organization andcellularity but also in height and volume215. In the human
tibial plateau or medial femoral condyle, a shallow full-
thickness defect would span a height of approximately
2–4 mm, frequently cover an area of about 3–4 cm2 and
thus embrace a tissue volume of 0.9–1.0 cm3 (i.e., ml),
which represents a vast void to be filled with engineered
tissue. Indeed, routine tissue culturing methodologies
cannot cope with this scale of production, which requires
the use of special technologies, such as bioreactor
systems256,459–461. Albeit so, it is still absolutely essential
that investigators give due consideration to defect design in
their chosen animal model, so as to be able to simulate as
closely as possible the human situation aimed at (see next
section).
DEFECT DESIGN IN ANIMAL MODELS
A survey of the literature pertaining to tissue engineering
aspects of articular cartilage repair reveals a depressing
consistency in the degree to which investigators disregard
defect dimensions relative to the make-up of the tissue
surrounds and fail to consider their pertinence to the human
condition they ultimately wish to treat215. The first, most
fundamental, question to be asked is: do I wish to treat a
partial-thickness defect, which has no access to the blood
vascular spaces, or a full-thickness one, in which case the
influence of blood-borne cell populations and signaling
substances must be brought under control?
The creation of partial-thickness defects in most com-
monly used experimental animals poses great technical
difficulties owing to the small scale of the dimensions
involved, and these are not easily surmounted on a repro-
ducible basis. It is probably for this reason that most
investigators have chosen to work with full-thickness defect
models. But by so doing, they have, on the one hand, won
a head’s start for their treatment principle, in that any repair
response elicited will be promoted or boosted by the
spontaneously-generated one. On the other hand, they
have thereby rendered an interpretation of their findings
more difficult, particularly if they have failed to set up
systematically the control experiments required for the
drawing of unequivocal conclusions. The volumes of
such full-thickness defects are, of course, more akin to
those of partial-thickness ones in human patients, but then
450 E. B. Hunziker: Articular cartilage repairappropriate measures must be taken to render the micro-
environment alike too. One means of achieving this is to
create a so-called ‘virtual’ partial-thickness defect, which
would involve treating the floor and walls of a full-thickness
one in such a manner as to render it impermeable to
blood-borne cells and signaling substances emanating
from the subchondral bone-tissue spaces421.
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